Intarcia inks antibody deal with Numab; Sanofi moves toward GLP-1 filing;

@FierceBiotech: ICYMI: Retrophin bags rare disease approval, FDA voucher in $75M deal. Article | Follow @FierceBiotech

@JohnCFierce: The interesting headline on the top revenue report, $LLY gets nudged out of top 10 by a booming $GILD--$LLY now #14. FiercePharma feature | Follow @JohnCFierce

@DamianFierce: Here are some particularly tight #FierceMadness matchups in Round 1. Cast your votes here | Follow @DamianFierce

> Intarcia Therapeutics partnered up with Switzerland's Numab to develop new antibodies for metabolic and autoimmune diseases, paying an undisclosed up-front payment to expand its pipeline beyond the Phase III ITCA 650. More

> AbbVie ($ABBV) signed a deal with C2N Diagnostics to get its hands on some anti-tau protein antibodies for Alzheimer's disease. News

> Amgen ($AMGN) submitted evolocumab, its PCSK9-blocking treatment for high cholesterol, for Japanese approval. Item

> Sanofi ($SNY) says its GLP-1 diabetes drug lixisenatide didn't increase cardiovascular risks in a late-stage outcomes study, clearing the way for an FDA submission. Story

Medical Device News

@FierceMedDev: Roche joins forces with Sigma-Aldrich to distribute biochemical reagents. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: I'm going to skip work and fill out my #FierceMadness bracket at the bar! Check it out | Follow @VarunSaxena2

@EmilyWFierce: Merck KGaA to tap Oschmann as new CEO, sources report. Article | Follow @EmilyWFierce

> Philips to help fund HealthTech refocus with 2016 lighting biz IPO. Story

> GE tech hub develops innovative handheld probe for bedsore monitoring. Article

Pharma News

@FiercePharma: Remember, you can keep on voting in #FierceMadness Round 2 all through the weekend. Vote | Follow @FiercePharma

@EricPFierce: India's Micro Labs, whose Bangalore plant was banned by FDA, is recalling simvastatin made at Goa facility. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Another reason to vote in #FierceMadness: Once you do, you can see others' comments, which so far have proven to be my favorite thing ever. | Follow @CarlyHFierce

> GSK's Breo for asthma? FDA panel says yes--but only in adults. News

> Merck KGaA to tap Oschmann as new CEO, sources report. Report

> Judge says Novartis can launch biosimilar of Amgen's Neupogen. Article

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.